Evidence map›Paper›PMID 24299204›Full record

ArticleEpilepsia2014

A potassium leak channel silences hyperactive neurons and ameliorates status epilepticus.

Deblina Dey, Veit-Simon Eckle, Iuliia Vitko, Kyle A Sullivan, Zofia M Lasiecka, Bettina Winckler, Ruth L Stornetta, John M Williamson, Jaideep Kapur, Edward Perez-Reyes

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Genetic medicines for epilepsy: unlocking new avenues for seizure control.Frontiers in bioengineering and biotechnology · 2026
    Review
  2. Article
  3. TREK-1 and epilepsy: regulating the balance of KBehavioral and brain functions : BBF · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Voltage-Gated NaLife (Basel, Switzerland) · 2023
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. The role of two-pore-domain background K⁺ (K₂p) channels in the thalamus.Pflugers Archiv : European journal of physiology · 2015
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Deblina DeyDepartment of Pharmacology, Graduate Program University of Virginia School of Medicine, Charlottesville, Virginia, U.S.A; Department of Neuroscience, Graduate Program University of Virginia School of Medicine, Charlottesville, Virginia, U.S.A.
Veit-Simon Eckle
Iuliia Vitko
Kyle A Sullivan
Zofia M Lasiecka
Bettina Winckler
Ruth L Stornetta
John M Williamson
Jaideep Kapur
Edward Perez-Reyes
University of Virginia · US

Funding

TREATMENT OF STATUS EPILEPTICUSR01NS040337 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2000 to 2021
$5.0M
Neurosteroid Regulation of SeizuresR01NS044370 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2003 to 2017
$4.1M
NINDS NIH HHS NS040337NINDS NIH HHS R01 NS040337NINDS NIH HHS R01 NS044370
6 · The paper itself

Abstract

objectiveTo develop a constitutively active K(+) leak channel using TREK-1 (TWIK-related potassium channel 1; TREK-M) that is resistant to compensatory down-regulation by second messenger cascades, and to validate the ability of TREK-M to silence hyperactive neurons using cultured hippocampal neurons. To test if adenoassociated viral (AAV) delivery of TREK-M could reduce the duration of status epilepticus and reduce neuronal death induced by lithium-pilocarpine administration.

methodsMolecular cloning techniques were used to engineer novel vectors to deliver TREK-M via plasmids, lentivirus, and AAV using a cytomegalovirus (CMV)-enhanced GABRA4 promoter. Electrophysiology was used to characterize the activity and regulation of TREK-M in human embryonic kidney (HEK-293) cells, and the ability to reduce spontaneous activity in cultured hippocampal neurons. Adult male rats were injected bilaterally with self-complementary AAV particles composed of serotype 5 capsid into the hippocampus and entorhinal cortex. Lithium-pilocarpine was used to induce status epilepticus. Seizures were monitored using continuous video-electroencephalography (EEG) monitoring. Neuronal death was measured using Fluoro-Jade C staining of paraformaldehyde-fixed brain slices.

resultsTREK-M inhibited neuronal firing by hyperpolarizing the resting membrane potential and decreasing input resistance. AAV delivery of TREK-M decreased the duration of status epilepticus by 50%. Concomitantly it reduced neuronal death in areas targeted by the AAV injection. SIGNIFICANCE: These findings demonstrate that TREK-M can silence hyperexcitable neurons in the brain of epileptic rats and treat acute seizures. This study paves the way for an alternative gene therapy treatment of status epilepticus, and provides the rationale for studies of AAV-TREK-M's effect on spontaneous seizures in chronic models of temporal lobe epilepsy.

Indexed as

Gene Transfer TechniquesAnimalsCell DeathCell PolarityGenetic VectorsHEK293 CellsHumansMaleNeural InhibitionNeuronsPotassium Channels, Tandem Pore DomainRatsRats, Sprague-DawleyStatus Epilepticuspotassium channel protein TREK-1Potassium Channels, Tandem Pore DomainGene therapyHippocampusPotassium currentsStatus epilepticusTemporal lobe epilepsyT-type calcium channel

Identifiers

PMID24299204
PMCPMC4161023
OpenAlexW2007429002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.